Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 340

1.

Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission.

Eom KS, Shin SH, Yoon JH, Yahng SA, Lee SE, Cho BS, Kim YJ, Kim HJ, Min CK, Kim DW, Lee JW, Min WS, Park CW, Lee S.

Am J Hematol. 2013 Aug;88(8):634-41. doi: 10.1002/ajh.23465.

2.

Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.

Cho BS, Lee S, Kim YJ, Chung NG, Eom KS, Kim HJ, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Kim CC.

Leukemia. 2009 Oct;23(10):1763-70. doi: 10.1038/leu.2009.102.

PMID:
19440217
3.

Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.

Chen YB, Coughlin E, Kennedy KF, Alyea EP, Armand P, Attar EC, Ballen KK, Cutler C, Dey BR, Koreth J, McAfee SL, Spitzer TR, Antin JH, Soiffer RJ, Ho VT.

Biol Blood Marrow Transplant. 2013 Jun;19(6):981-7. doi: 10.1016/j.bbmt.2013.03.016.

4.

Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation.

Mohty M, Labopin M, Volin L, Gratwohl A, Socié G, Esteve J, Tabrizi R, Nagler A, Rocha V; Acute Leukemia Working Party of EBMT..

Blood. 2010 Nov 25;116(22):4439-43. doi: 10.1182/blood-2010-02-266551.

5.

Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.

Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.

Haematologica. 2002 Jan;87(1):52-8.

6.

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.

Goker H, Ozdemir E, Uz B, Buyukasik Y, Turgut M, Serefhanoglu S, Aksu S, Sayinalp N, Haznedaroglu IC, Tekin F, Karacan Y, Unal S, Eliacik E, Isik A, Ozcebe OI.

Transfus Apher Sci. 2013 Dec;49(3):590-9. doi: 10.1016/j.transci.2013.07.030.

PMID:
23981652
7.

The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission.

Marks DI, Wang T, Pérez WS, Antin JH, Copelan E, Gale RP, George B, Gupta V, Halter J, Khoury HJ, Klumpp TR, Lazarus HM, Lewis VA, McCarthy P, Rizzieri DA, Sabloff M, Szer J, Tallman MS, Weisdorf DJ.

Blood. 2010 Jul 22;116(3):366-74. doi: 10.1182/blood-2010-01-264077.

8.

Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.

Le Bourgeois A, Mohr C, Guillaume T, Delaunay J, Malard F, Loirat M, Peterlin P, Blin N, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Lode L, Bene MC, Chevallier P.

Biol Blood Marrow Transplant. 2013 Jun;19(6):934-9. doi: 10.1016/j.bbmt.2013.03.009.

9.

Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.

Tang W, Wang L, Zhao WL, Chen YB, Shen ZX, Hu J.

Biol Blood Marrow Transplant. 2011 Oct;17(10):1555-61. doi: 10.1016/j.bbmt.2011.04.003.

10.

Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.

Rubio MT, Savani BN, Labopin M, Piemontese S, Polge E, Ciceri F, Bacigalupo A, Arcese W, Koc Y, Beelen D, Gülbas Z, Wu D, Santarone S, Tischer J, Afanasyev B, Schmid C, Giebel S, Mohty M, Nagler A.

J Hematol Oncol. 2016 Mar 15;9:25. doi: 10.1186/s13045-016-0248-3.

11.

The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy.

Cook G, Clark RE, Crawley C, Mackinnon S, Russell N, Thomson K, Pearce RM, Towlson K, Marks DI.

Biol Blood Marrow Transplant. 2006 Mar;12(3):293-300.

12.

Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.

Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, Van Biezen A, Michallet M, Niederwieser D; Chronic Leukemia Working Party of the EBMT..

Leukemia. 2003 May;17(5):841-8. Review.

PMID:
12750695
13.

Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.

Pérez-Simón JA, Díez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD, de León A, Valcárcel D, Carreras E, del Cañizo MC, López-Fidalgo J, Sierra J, San Miguel JF.

Br J Haematol. 2005 Aug;130(3):394-403.

PMID:
16042689
14.
15.

Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.

J Clin Oncol. 2008 Feb 1;26(4):577-84.

PMID:
18086801
16.

Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.

Abdul Wahid SF, Ismail NA, Mohd-Idris MR, Jamaluddin FW, Tumian N, Sze-Wei EY, Muhammad N, Nai ML.

Stem Cells Dev. 2014 Nov 1;23(21):2535-52. doi: 10.1089/scd.2014.0123. Review.

17.

Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.

Oyekunle AA, Kröger N, Zabelina T, Ayuk F, Schieder H, Renges H, Fehse N, Waschke O, Fehse B, Kabisch H, Zander AR.

Bone Marrow Transplant. 2006 Jan;37(1):45-50.

PMID:
16258531
18.

Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease.

Yanada M, Naoe T, Iida H, Sakamaki H, Sakura T, Kanamori H, Kodera Y, Okamoto S, Kanda Y, Sao H, Asai O, Nakai K, Maruta A, Kishi K, Furukawa T, Atsuta Y, Yamamoto K, Tanaka J, Takahashi S.

Bone Marrow Transplant. 2005 Nov;36(10):867-72.

PMID:
16113659
19.

Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease.

Lee S, Cho BS, Kim SY, Choi SM, Lee DG, Eom KS, Kim YJ, Kim HJ, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Shin WS, Kim CC.

Biol Blood Marrow Transplant. 2007 Sep;13(9):1083-94.

20.

Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients.

Topcuoglu P, Arat M, Ozcan M, Arslan O, Ilhan O, Beksac M, Gurman G.

Ann Hematol. 2012 Apr;91(4):577-86. doi: 10.1007/s00277-011-1349-2.

PMID:
21971669

Supplemental Content

Support Center